266 related articles for article (PubMed ID: 23928856)
1. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.
Sun N; Zhao H
Biotechnol Bioeng; 2014 May; 111(5):1048-53. PubMed ID: 23928856
[TBL] [Abstract][Full Text] [Related]
2. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
[TBL] [Abstract][Full Text] [Related]
3. TALEN-mediated generation and genetic correction of disease-specific human induced pluripotent stem cells.
Ramalingam S; Annaluru N; Kandavelou K; Chandrasegaran S
Curr Gene Ther; 2014; 14(6):461-72. PubMed ID: 25245091
[TBL] [Abstract][Full Text] [Related]
4. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
5. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
6. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells.
Ma N; Liao B; Zhang H; Wang L; Shan Y; Xue Y; Huang K; Chen S; Zhou X; Chen Y; Pei D; Pan G
J Biol Chem; 2013 Nov; 288(48):34671-9. PubMed ID: 24155235
[TBL] [Abstract][Full Text] [Related]
7. Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.
Sun N; Liang J; Abil Z; Zhao H
Mol Biosyst; 2012 Apr; 8(4):1255-63. PubMed ID: 22301904
[TBL] [Abstract][Full Text] [Related]
8. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases.
Sebastiano V; Maeder ML; Angstman JF; Haddad B; Khayter C; Yeo DT; Goodwin MJ; Hawkins JS; Ramirez CL; Batista LF; Artandi SE; Wernig M; Joung JK
Stem Cells; 2011 Nov; 29(11):1717-26. PubMed ID: 21898685
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells.
Park S; Gianotti-Sommer A; Molina-Estevez FJ; Vanuytsel K; Skvir N; Leung A; Rozelle SS; Shaikho EM; Weir I; Jiang Z; Luo HY; Chui DHK; Figueiredo MS; Alsultan A; Al-Ali A; Sebastiani P; Steinberg MH; Mostoslavsky G; Murphy GJ
Stem Cell Reports; 2017 Apr; 8(4):1076-1085. PubMed ID: 28111279
[TBL] [Abstract][Full Text] [Related]
10. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.
Zou J; Mali P; Huang X; Dowey SN; Cheng L
Blood; 2011 Oct; 118(17):4599-608. PubMed ID: 21881051
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
Hoban MD; Lumaquin D; Kuo CY; Romero Z; Long J; Ho M; Young CS; Mojadidi M; Fitz-Gibbon S; Cooper AR; Lill GR; Urbinati F; Campo-Fernandez B; Bjurstrom CF; Pellegrini M; Hollis RP; Kohn DB
Mol Ther; 2016 Sep; 24(9):1561-9. PubMed ID: 27406980
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of induced pluripotent stem cell line (IGIBi001-A) from a sickle cell anemia patient with homozygous β-globin mutation.
Bhargava N; Jaitly S; Goswami SG; Jain S; Chakraborty D; Ramalingam S
Stem Cell Res; 2019 Aug; 39():101484. PubMed ID: 31255831
[TBL] [Abstract][Full Text] [Related]
13. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.
Xie F; Ye L; Chang JC; Beyer AI; Wang J; Muench MO; Kan YW
Genome Res; 2014 Sep; 24(9):1526-33. PubMed ID: 25096406
[TBL] [Abstract][Full Text] [Related]
14. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
15. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
16. Nuclease-mediated gene editing by homologous recombination of the human globin locus.
Voit RA; Hendel A; Pruett-Miller SM; Porteus MH
Nucleic Acids Res; 2014 Jan; 42(2):1365-78. PubMed ID: 24157834
[TBL] [Abstract][Full Text] [Related]
17. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
18. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
Li L; Yi H; Liu Z; Long P; Pan T; Huang Y; Li Y; Li Q; Ma Y
Stem Cell Res Ther; 2022 Mar; 13(1):102. PubMed ID: 35255977
[TBL] [Abstract][Full Text] [Related]
19. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice.
Wilkinson AC; Dever DP; Baik R; Camarena J; Hsu I; Charlesworth CT; Morita C; Nakauchi H; Porteus MH
Nat Commun; 2021 Jan; 12(1):686. PubMed ID: 33514718
[TBL] [Abstract][Full Text] [Related]
20. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
Moiani A; Letort G; Lizot S; Chalumeau A; Foray C; Felix T; Le Clerre D; Temburni-Blake S; Hong P; Leduc S; Pinard N; Marechal A; Seclen E; Boyne A; Mayer L; Hong R; Pulicani S; Galetto R; Gouble A; Cavazzana M; Juillerat A; Miccio A; Duclert A; Duchateau P; Valton J
Nat Commun; 2024 Jun; 15(1):4965. PubMed ID: 38862518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]